Journal: 2017 Volumes
Dear Colleagues, As the 2020 pandemic has altered our behavioral, economic, educational policies, and numerous other career and life events worldwide, SARS-CoV-2 has also impacted global healthcare and patient outcomes. Fortunately, and not unexpectedly, frontline and advanced line healthcare workers, researchers, and scientists have never ceased the tradition of tireless sacrifice and dedication to advancing patient care. Assuredly we have reviewed and read exceptional cancer care advancements in 2020, including innovative efforts for delivering care via ambulatory processes or through virtual technologies while prioritizing our most vulnerable patient populations. Fortunately, numerous diagnostic and therapeutic advancements in 2020 have occurred in Genitourinary Oncology.
While safeguarding both patients and the healthcare team from unnecessary risk of SARS-CoV-2, telehealth technology and its widespread adoption among healthcare practitioners and patients have allowed for innovative patient care strategies. Virtual education has also persevered and improved during this year of in-person and travel adversity.
Neal D. Shore, MD, FACS is the Medical Director for the Carolina Urologic Research Center. He practices with Atlantic Urology Clinics in Myrtle Beach, South Carolina. Dr. Shore has conducted more than 350 clinical trials, focusing mainly on GU Oncology, and serves on the Executive Boards of: Society of Urologic Oncology Board, Bladder Cancer Advocacy Network, and is Immediate Past President, Large Urology Group Practice Association. He is a founder for both: CUSP Clinical Trials Consortium, as well as for DASHKO, large urology practices data registries. He serves as the National Urology Research Director for 21st Century Oncology. He has served on the AUA Male Health Committee and the AUA Data Committee, the SITC Task Force for Prostate Cancer, the Bladder Cancer Advocacy Think Tank and the editorial boards of Reviews in Urology, Urology Times, Chemotherapy Advisor, OncLive, PLOS ONE (Academic Editor), Urology Practice, World Journal of Urology, and serves as Editor, Everyday Urology-Oncology. He has more than 200 peer-reviewed publications and numerous book chapters; he performs peer review for Lancet Oncology, New England Journal of Medicine, European Urology, Journal Urology, Urology, BJUI, PCPD, and numerous other high impact scientific journals. A graduate of Duke University and Duke University Medical School, Dr. Shore completed a 6-month clinical research fellowship in Pretoria, South Africa, and then completed his General Surgery/Urology training at New York Hospital Cornell Medical Center and at Memorial Sloan-Kettering Cancer Center in New York City. He is a Fellow of the American College of Surgeons.
In this issue
- Enhanced Recovery After Surgery, Radical Cystectomy and Urinary Diversion
- Assessment of Cardiovascular Risk With the Use of Androgen Deprivation Therapy for Prostate Cancer
- Radium-223:The Only Approved Targeted Alpha Therapy (TAT) in mCRPC- Outcomes, Opportunities and Lessons Learned